Genuine Biotech Enters into a Strategic Partnership with Insilico Medicine to Accelerate Innovative Drug Development Using AI

Recently, Genuine Biotech and Insilico Medicine, a leading AI drug discovery and development company in the industry, announced a strategic collaboration.

According to the strategic cooperation agreement, both parties will start innovative R&D cooperation in the fields of antiviral and antitumor drug development, as well as drug development for cardiovascular, cerebrovascular and liver diseases. The combination of successful innovative R&D experience of Genuine Biotech and the superior AI end-to-end drug development platform of Insilico Medicine will accelerate the development of innovative drugs by Genuine Biotech and result in breakthrough therapies for unmet clinical needs in related fields.

Genuine Biotech is an R&D-driven innovative drug company focusing on drug discovery and development for antiviral and antitumor purposes, as well as for cardiovascular, cerebrovascular, and liver diseases. The company's management and R&D team are of the highest caliber, and the core team members all have experience working in prestigious overseas R&D institutions and a track record of successful new drug development.

Dr. Du Jinfa, the CEO and Chief Scientific Officer of Genuine Biotech, has nearly 30 years of experience in the development of antiviral and antitumor therapeutics. He is the inventor and head of project development of sofosbuvir (SovaIdi), a breakthrough new medication to cure hepatitis C. Sofosbuvir which was acquired by Gilead in 2011 and has become a revolutionary and legendary drug with annual sales of $10 billion.

Dr. Dang Qun, the President of the company, has been engaged in new drug development for nearly 30 years and has led the preclinical and clinical development of dozens of drugs, covering various fields such as tumor, metabolism, antiviral therapeutics, antibacterial therapeutics, as well as cardiovascular and cerebrovascular diseases.

Since its establishment, Genuine Biotech has been dedicated to innovative drug discovery and development and has achieved great results. On Jul. 22, 2021, the world's first dual-target anti-HIV drug Azvudine (FNC), independently developed by Genuine Biotech, was approved for marketing, providing a new treatment option for patients infected with HIV-1. In addition to Azvudine, Genuine Biotech has also independently developed a number of new drugs. One of them is a new Class 1 drug for the treatment of non-small cell lung cancer, dosimertinib, which has been approved for clinical research in China. In addition, several new Class 1 drugs, such as next-generation cardiovascular and cerebrovascular therapeutics and long-acting HIV therapeutics, are in preclinical research.

As for this strategic cooperation, Dr. Dang Qun, President of Genuine Biotech, stated, "Insilico Medicine is a leading international company applying AI technology platform for target discovery, design and clinical development of innovative drugs. The R&D team of Genuine Biotech has rich and successful drug design experience and R&D capabilities. The combination of successful innovative drug development experience of Genuine Biotech and the AI technology platform of Insilico Medicine will strongly accelerate the innovative drug development process of Genuine Biotech and continue to provide new and better treatment options for patients."

Dr. Ren Feng, Chief Scientific Officer of Insilico Medicine, stated, "We are honored to enter into a partnership with Genuine Biotech, one of the representatives of innovative biopharmaceutical companies in China. Recently, the new anti-HIV Class I antiviral drug independently developed by Genuine Biotech was successfully launched, fully demonstrating Genuine Biotech's ability to develop new drugs in the antivirals field. The end-to-end AI drug discovery and development platform of Insilico Medicine is based on unique training models and massive data validation. This platform is expected to further empower Genuine Biotech's innovations at source and bring efficient solutions to unmet clinical needs."